Clinical Trial

The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
micro-PET imaging showed that 18F-PSMA-1007 had similar or even better pharmacokinetics and imaging performance than 18F-DCFPyL. Due to the convenience of synthesis and good imaging performance, 18F-PSMA-1007 is expected to be popularized in clinical practice.The purpose of this study is to evaluate the performance of 18F-PSMA-1007 in diagnosis, differential diagnosis and efficacy monitoring of prostate cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-05; most recent amendment 2025-01-23.
Trial Details
NCT Number NCT06723665
Lead Sponsor Affiliated Hospital of Jiangnan University
Conditions Prostate Cancer
Enrollment 50 participants
Start Date 2024-01-25
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-24